Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Eur Urol Retrieve available abstracts of 276 articles: HTML format

Single Articles

September 2025
1. LIU H, Sun F, Wu J
   Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. https://doi.org/10.1016/j.e
   Eur Urol. 2025 Sep 27:S0302-2838(25)04691-3. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
2. CONTEDUCA V, Bruno G, Landriscina M
   Reconciling Clinical and Molecular Heterogeneity in Metastatic Castration-resistant Prostate Cancer: The Promise of Integrated Prognostic Models.
   Eur Urol. 2025 Sep 27:S0302-2838(25)04676-7. doi: 10.1016/j.eururo.2025.09.4140.
   PubMed    
   
   
   
3. ARTAMONOVA N, Heidegger I
   Re: Pao-Hwa Lin, Alanna D. Burwell, Edward L. Giovannucci, et al. Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials. Eur Urol. In press. https://doi.org/10.1
   Eur Urol. 2025 Sep 27:S0302-2838(25)04697-4. doi: 10.1016/j.eururo.2025.09.4147.
   PubMed    
   
   
   
4. WANG Y, Lu Q, Zhao X
   Re: Lars Holmberg, Hans Garmo, Sven-Olov Andersson, et al. Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2
   Eur Urol. 2025 Sep 27:S0302-2838(25)04696-2. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
5. BERNARDINO RM, van der Kwast T, Fleshner NE
   Reply to Nour Khalil, Guiseppe Maiolino, and Eric Barret's Letter to the Editor re: Rui M. Bernardino, Theodorus van der Kwast, Neil E. Fleshner. Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives. Eu
   Eur Urol. 2025 Sep 27:S0302-2838(25)04689-5. doi: 10.1016/j.eururo.2025.09.4146.
   PubMed    
   
   
   
6. STRAUSS AS, Cleves A, Dahm P
   Re: Elio Mazzone, Alice Thomson, David C. Chen, et al. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer Aft
   Eur Urol. 2025 Sep 26:S0302-2838(25)04651-2. doi: 10.1016/j.eururo.2025.09.4131.
   PubMed    
   
   
   
7. MONTORSI F, Zaurito P, Gandaglia G
   Re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol 2025;88:167-75.
   Eur Urol. 2025 Sep 26:S0302-2838(25)04685-8. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
8. FISHER DJ, Burdett S, Vale CL
   Reply to Shenglong Li and Cuicui Wang's Letter to the Editor re: Sarah Burdett, David J. Fisher, Jayne F. Tierney, et al. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Sy
   Eur Urol. 2025 Sep 25:S0302-2838(25)04653-6. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
9. MONTIRONI R, Cimadamore A, Lopez-Beltran A, Cheng L, et al
   Re: Lucia L. Rijstenberg, Hridya Harikumara, Esther I. Verhoef, et al. Identification of Intraductal-to-Invasive Spatial Transitions in Prostate Cancer: Proposal for a New Unifying Model on Intraductal Carcinogenesis. Histopathology 2025;86:1091-100.
   Eur Urol. 2025 Sep 25:S0302-2838(25)04656-1. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
10. MISZCZYK M, Sanchez-Salas R, Emberton M, Shariat SF, et al
    Re: Karolina Menne Guricova, Cedric Draulans, Floris J. Pos, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial. J Clin Oncol. In press. https:/
    Eur Urol. 2025 Sep 24:S0302-2838(25)04650-0. doi: 10.1016/j.eururo.2025.09.4133.
    PubMed    
    
    
    
11. PALMSTEDT E, Hugosson J, Arnsrud Godtman R
    Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extende
    Eur Urol. 2025 Sep 24:S0302-2838(25)04644-5. doi: 10.1016/j.eururo.2025.09.4130.
    PubMed    
    
    
    
12. GINSBURG KB, Zamani A, Borza T
    Re: Emmeli Palmstedt, Marianne Mansson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial. Eur Urol. In press. https:/
    Eur Urol. 2025 Sep 24:S0302-2838(25)04647-0. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
13. STABILE A, Montorsi F
    Re: Arvin K. George, Ranko Miocinovic, Amit R. Patel, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. In press. https://doi.org/10.1016/j.e
    Eur Urol. 2025 Sep 23:S0302-2838(25)04641-X. doi: 10.1016/j.eururo.2025.09.4128.
    PubMed    
    
    
    
14. ENGLMAN C, Adebusoye B, Mallett S, Giganti F, et al
    Reply to Yuan Du, Dan Liu, and Zhihui Guan's Letter to the Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Stu
    Eur Urol. 2025 Sep 18:S0302-2838(25)00500-7. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
15. DU Y, Liu D, Guan Z
    Re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.03.0
    Eur Urol. 2025 Sep 9:S0302-2838(25)00478-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
16. LI J, Zhang Y, Hu H
    Re: Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol.
    Eur Urol. 2025 Sep 8:S0302-2838(25)00483-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
17. LI S, Wang C
    Re: Sarah Burdett, David J Fisher, Jayne F. Tierney, et al. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol.
    Eur Urol. 2025 Sep 6:S0302-2838(25)00480-4. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    August 2025
18. LIN PH, Burwell AD, Giovannucci EL, Loeb S, et al
    Dietary Patterns in Prostate Cancer Prevention and Management: A Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials.
    Eur Urol. 2025 Aug 19:S0302-2838(25)00433-6. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
19. SCUDERI S, Gandaglia G, Briganti A, Montorsi F, et al
    Re: Prostate Cancer: A Review.
    Eur Urol. 2025 Aug 19:S0302-2838(25)00437-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
20. DEMOGEOT N, Sargos P, Salleron J, Guerif S, et al
    Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.
    Eur Urol. 2025 Aug 14:S0302-2838(25)00436-1. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
21. SANTIAGO I, Rivas JG
    Re: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer.
    Eur Urol. 2025 Aug 13:S0302-2838(25)00440-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
22. FAHRNER M, Zamboglou C, Spohn SKB, Oerther B, et al
    Advancing Radioproteomics: Integration of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Localized Proteomic Profiling in Prostate Cancer.
    Eur Urol. 2025 Aug 11:S0302-2838(25)00393-8. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
23. MONTORSI F, Barletta F, Gandaglia G, Briganti A, et al
    Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial.
    Eur Urol. 2025 Aug 11:S0302-2838(25)00400-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
24. HALABI S, Guo S, Luo B, Yu C, et al
    Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
    Eur Urol. 2025 Aug 6:S0302-2838(25)00407-5. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    July 2025
25. SHERRY AD, Siddiqui BA, Haymaker C, Fellman BM, et al
    Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.
    Eur Urol. 2025 Jul 31:S0302-2838(25)00396-3. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
26. HOLMBERG L, Garmo H, Andersson SO, Andren O, et al
    Time Dependence of Outcomes in the SPCG-4 Randomized Trial Comparing Radical Prostatectomy and Watchful Waiting in Early Prostate Cancer.
    Eur Urol. 2025 Jul 30:S0302-2838(25)00390-2. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
27. THOMAS C, Hadaschik B
    Re: Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V-STORM): A Phase 2, Open-label, Randomised Controlled Trial.
    Eur Urol. 2025 Jul 30:S0302-2838(25)00398-7. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
28. TURKBEY B, Schoots IG, Haider MA
    Reply to Masatomo Kaneko, Vasileios Magoulianitis, Vinay Duddalwar, et al's Letter to the Editor re: Baris Turkbey, Henkjan Huisman, Andriy Fedorov, et al. Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-naive
    Eur Urol. 2025 Jul 28:S0302-2838(25)00395-1. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
29. ALBERS P
    Re: Local Anaesthetic Transperineal Biopsy Versus Transrectal Prostate Biopsy in Prostate Cancer Detection (TRANSLATE): A Multicentre, Randomised, Controlled Trial.
    Eur Urol. 2025 Jul 25:S0302-2838(25)00401-4. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
30. VAN DEN BERGH RCN, van der Poel HG, van Leeuwen PJ, van Soest RJ, et al
    Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial.
    Eur Urol. 2025 Jul 25:S0302-2838(25)00399-9. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
31. CIMADAMORE A, Boixareu C, Sharp A, Beltran H, et al
    Novel Therapeutic Strategies for Metastatic Prostate Cancer Care.
    Eur Urol. 2025 Jul 19:S0302-2838(25)00357-4. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
32. GEORGE AK, Miocinovic R, Patel AR, Lomas DJ, et al
    Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.
    Eur Urol. 2025 Jul 19:S0302-2838(25)00346-X. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
33. COVAS MOSCHOVAS M, Saikali S, Sandri M, Bravi C, et al
    Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robotic Urology Section Scientific Working Group.
    Eur Urol. 2025;88:103-113.
    PubMed     Abstract available
    
    
    June 2025
34. CARLSSON SV
    Rethinking Early Detection: Magnetic Resonance Imaging Strategies for Smarter Prostate Cancer Screening.
    Eur Urol. 2025 Jun 25:S0302-2838(25)00356-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
35. PALMSTEDT E, Mansson M, Hugosson J, Arnsrud Godtman R, et al
    Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GOTEBORG-1 Trial.
    Eur Urol. 2025 Jun 25:S0302-2838(25)00358-6. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
36. BURDETT S, Fisher DJ, Tierney JF, Cook AD, et al
    Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.
    Eur Urol. 2025 Jun 25:S0302-2838(25)00291-X. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
37. KARPINSKI MJ, Hadaschik BA, Fendler WP
    Reply to Zhengbo Pan, Run Shi, and Zhaokai Zhou's Letter to the Editor - Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bogemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate
    Eur Urol. 2025 Jun 23:S0302-2838(25)00349-5. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
38. DAVIS ID
    If the Treatment for Metastatic Hormone-sensitive Prostate Cancer Stops Working, What Next?
    Eur Urol. 2025 Jun 21:S0302-2838(25)00354-9. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
39. PAN Z, Shi R, Zhou Z
    Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bogemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an
    Eur Urol. 2025 Jun 20:S0302-2838(25)00352-5. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
40. KANEKO M, Magoulianitis V, Duddalwar V, Aron M, et al
    Re: Baris Turkbey, Henkjan Huisman, Andriy Fedorov, et al. Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-Naive Men: PI-RADS Steering Committee, Version 1.0. Radiology 2025;315:e24014.
    Eur Urol. 2025 Jun 20:S0302-2838(25)00351-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
41. GRIMM MO, Smith M, Hussain M, Saad F, et al
    Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial.
    Eur Urol. 2025 Jun 20:S0302-2838(25)00340-9. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
42. SCHOOTS IG, Ahmed HU, Albers P, Asbach P, et al
    Magnetic Resonance Imaging-based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review.
    Eur Urol. 2025 Jun 12:S0302-2838(25)00341-0. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
43. COOPERBERG MR, Grummet J, Eggener SE
    Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach. Eur Urol. In press. htt
    Eur Urol. 2025 Jun 12:S0302-2838(25)00331-8. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
44. KRISTIANSEN G, Paner GP, Shah RB
    Reply to Matthew R. Cooperberg, Jeremy Grummet, and Scott E. Eggener's Letter to the Editor re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defin
    Eur Urol. 2025 Jun 7:S0302-2838(25)00330-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
45. SHERRYN S, Baskoro B, Sun J
    Re: Veeru Kasivisvanathan, Vinson Wai-Shun Chan, Keiran D. Clement, et al. An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Det
    Eur Urol. 2025 Jun 7:S0302-2838(25)00332-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
46. ALBERTSEN P
    Re: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
    Eur Urol. 2025 Jun 6:S0302-2838(25)00328-8. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
47. AL-MONAJJED R, Boschheidgen M, Lakes J, Krilaviciute A, et al
    Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging-targeted Biopsy in the PROBASE Trial.
    Eur Urol. 2025 Jun 2:S0302-2838(25)00298-2. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
48. JOSEFSSON A, Carlsson SV, Lilja H, Godtman R, et al
    Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Andreas Josefsson, Marianne Mansson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in th
    Eur Urol. 2025;87:e112-e113.
    PubMed    
    
    
    
49. DE BONO JS, He M, Shi Z, Nowicka M, et al
    Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.
    Eur Urol. 2025;87:672-682.
    PubMed     Abstract available
    
    
    May 2025
50. ENGLMAN C, Adebusoye B, Maffei D, Stavrinides V, et al
    Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study.
    Eur Urol. 2025 May 27:S0302-2838(25)00192-7. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
51. LI KD, Carlisle MN, Jarosek S, Patel HV, et al
    Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data.
    Eur Urol. 2025 May 22:S0302-2838(25)00293-3. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
52. LEE W, Chung JY, Baidoo KE, Nambiar D, et al
    Glypican-3 as a Radiotheranostic Target for Neuroendocrine Prostate Cancer.
    Eur Urol. 2025 May 21:S0302-2838(25)00284-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
53. MAZZONE E, Thomson A, Chen DC, Cannoletta D, et al
    The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-a
    Eur Urol. 2025 May 19:S0302-2838(25)00285-4. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
54. COOPERBERG MR
    Prostate Cancer Active Surveillance Without Biopsy? Not Quite Yet, but Watch This Space.
    Eur Urol. 2025 May 19:S0302-2838(25)00286-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
55. HENNES D, Al-Khanaty A, Chen DC, Dineen E, et al
    Re: Local Anaesthetic Transperineal Biopsy Versus Transrectal Prostate Biopsy in Prostate Cancer Detection (TRANSLATE): A Multicentre, Randomised, Controlled Trial.
    Eur Urol. 2025 May 16:S0302-2838(25)00288-X. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
56. CHU G, Li Z, Niu H
    Re: Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
    Eur Urol. 2025 May 16:S0302-2838(25)00289-1. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
57. CHEN DC, Al-Khanaty A, Hennes D, Perera ML, et al
    Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial.
    Eur Urol. 2025 May 9:S0302-2838(25)00262-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
58. LI Y, Xie N, Chen R, Lee AR, et al
    Corrigendum to "RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression" [Eur. Urol. 76(2) (2019) 157-166].
    Eur Urol. 2025 May 7:S0302-2838(25)00261-1. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
59. ULERI A, Baboudjian M, Ploussard G
    Re: Richard J. Bryant, Ioana R. Marian, Roxanne Williams, et al. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. Lancet Oncol. In press. h
    Eur Urol. 2025 May 3:S0302-2838(25)00259-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
60. KARPINSKI MJ, Rahbar K, Bogemann M, Nikoukar LR, et al
    Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.
    Eur Urol. 2025 May 2:S0302-2838(25)00249-0. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
61. LAO Y, Guan X, Bai Y, Dong Z, et al
    Re: Aram Lyu, Zenghua Fan, Matthew Clark, et al. Evolution of Myeloid-mediated Immunotherapy Resistance in Prostate Cancer. Nature 2025;637:1207-17.
    Eur Urol. 2025 May 2:S0302-2838(25)00258-1. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
62. PLOUSSARD G, Coloby P, Chevallier T, Occean BV, et al
    Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.
    Eur Urol. 2025;87:526-533.
    PubMed     Abstract available
    
    
    April 2025
63. NG AB, Giganti F, Kasivisvanathan V
    Artificial Intelligence in Prostate Cancer Diagnosis on Magnetic Resonance Imaging: Time for a New PARADIGM.
    Eur Urol. 2025 Apr 30:S0302-2838(25)00252-0. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
64. GOMEZ RIVAS J, Moreno Sierra J
    Re: Darolutamide in Combination with Androgen-deprivation Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer from the Phase III ARANOTE Trial.
    Eur Urol. 2025 Apr 23:S0302-2838(25)00208-8. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
65. GOMEZ RIVAS J, Moreno Sierra J
    Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
    Eur Urol. 2025 Apr 22:S0302-2838(25)00207-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
66. VICKERS A, Touijer K
    Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2024;86:148-63.
    Eur Urol. 2025 Apr 12:S0302-2838(25)00200-3. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
67. ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al
    Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562
    Eur Urol. 2025 Apr 8:S0302-2838(25)00179-4. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
68. CHEN S, Xu H, Chen X, Shen Q, et al
    First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen-targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer.
    Eur Urol. 2025 Apr 8:S0302-2838(25)00182-4. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
69. ROBERTS MJ, Gandaglia G, Oprea-Lager DE, Stranne J, et al
    Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications.
    Eur Urol. 2025 Apr 7:S0302-2838(25)00154-X. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    March 2025
70. MAZZONE E, Cannoletta D, Quarta L, Chen DC, et al
    A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment.
    Eur Urol. 2025 Mar 27:S0302-2838(25)00155-1. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
71. MONTORSI F, Gandaglia G, Barletta F, Briganti A, et al
    Re: Andreas Josefsson, Marianne Mansson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial. Eur Urol 2024;86:223-9.
    Eur Urol. 2025 Mar 26:S0302-2838(25)00124-1. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
72. SHAH RB, Paner GP, Cheng L, De Marzo AM, et al
    Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach.
    Eur Urol. 2025 Mar 17:S0302-2838(25)00150-2. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
73. HAGE CHEHADE C, Ozay ZI, Ostrowski M, Mercinelli C, et al
    T-cell Engagers in Prostate Cancer.
    Eur Urol. 2025 Mar 11:S0302-2838(25)00070-3. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
74. DEVOS G, Giesen A, Joniau S
    When Less Is More: The Challenges of Defining Residual Disease Following Neoadjuvant Hormonal Therapy in Prostate Cancer.
    Eur Urol. 2025 Mar 10:S0302-2838(25)00146-0. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
75. TAHA T, Koster KL, de Bono JS
    T-Cell Engagers in Prostate Cancer: Promise, Challenges, and the Road Ahead.
    Eur Urol. 2025 Mar 5:S0302-2838(25)00147-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
76. GILLESSEN S, Tombal B, Turco F, Choudhury A, et al
    Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.
    Eur Urol. 2025;87:285-288.
    PubMed     Abstract available
    
    
    February 2025
77. FREEDLAND SJ, Mulhall JP, Gleave M, Giorgi U, et al
    Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study.
    Eur Urol. 2025 Feb 26:S0302-2838(25)00094-6. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
78. AZAD AA, Kostos L, Agarwal N, Attard G, et al
    Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2025 Feb 12:S0302-2838(25)00023-5. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
79. RAVI P, Kwak L, Acosta AM, Rastogi S, et al
    Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer.
    Eur Urol. 2025 Feb 6:S0302-2838(25)00027-2. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
80. CASTRO E, Lorente D, Olmos D
    PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the Chaff.
    Eur Urol. 2025 Feb 3:S0302-2838(25)00024-7. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
81. MORGAN TM, Daignault-Newton S, Spratt DE, Dunn RL, et al
    Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.
    Eur Urol. 2025;87:228-237.
    PubMed     Abstract available
    
    
    January 2025
82. BERNARDINO RM, van der Kwast T, Fleshner NE
    Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives.
    Eur Urol. 2025 Jan 30:S0302-2838(25)00025-9. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
83. NAQVI SAA, Riaz IB, Bibi A, Khan MA, et al
    Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.
    Eur Urol. 2025 Jan 22:S0302-2838(24)02760-X. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
84. MURTHY V, Marvaso G, Jereczek-Fossa BA, Thoma SA, et al
    The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care.
    Eur Urol. 2025 Jan 20:S0302-2838(25)00008-9. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
85. LONGONI M, Briganti A, Gandaglia G, Montorsi F, et al
    Re: Metastatic Hormone-sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.
    Eur Urol. 2025 Jan 10:S0302-2838(25)00001-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
86. LEENEN RCA, Roobol MJ, Beyer K
    Reply to Jonas Hugosson. Population-based Screening for Prostate Cancer: Is It Time? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.003.
    Eur Urol. 2025 Jan 4:S0302-2838(24)02767-2. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
87. EL-TAJI O, Clarke NW
    Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for Precision in Treatment Strategies.
    Eur Urol. 2025;87:27-28.
    PubMed    
    
    
    
88. ONG WL, Romero T, Roy S, Nikitas J, et al
    Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.
    Eur Urol. 2025;87:49-57.
    PubMed     Abstract available
    
    
    December 2024
89. STRANNE J, Henry A, Oprea-Lager DE
    Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum.
    Eur Urol. 2024 Dec 18:S0302-2838(24)02745-3. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
90. TISSEVERASINGHE S, Tolba M, Saad F, Fizazi K, et al
    Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
    Eur Urol. 2024 Dec 17:S0302-2838(24)02748-9. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
91. DIAS AB, Moore CM, Renard-Penna R, Giganti F, et al
    Biparametric Versus Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Choice or a Fine Balance?
    Eur Urol. 2024 Dec 16:S0302-2838(24)02740-4. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
92. DAVIS JW
    Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy-A New Standard for Guidelines on Prostate Cancer Detection?
    Eur Urol. 2024 Dec 11:S0302-2838(24)02717-9. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
93. SCHAFER EJ, Laversanne M, Sung H, Soerjomataram I, et al
    Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.
    Eur Urol. 2024 Dec 5:S0302-2838(24)02707-6. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    November 2024
94. MADEC FX, Mesnard B, Dariane C
    Re: Prevalence and Factors Associated with Prostate Cancer Among Transgender Women.
    Eur Urol. 2024 Nov 21:S0302-2838(24)02704-0. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
95. COOPERBERG MR
    Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
    Eur Urol. 2024 Nov 21:S0302-2838(24)02700-3. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
96. HUGOSSON J
    Population-based Screening for Prostate Cancer: Is it Time?
    Eur Urol. 2024 Nov 20:S0302-2838(24)02696-4. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
97. DAHM P, Wilt TJ
    Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
    Eur Urol. 2024 Nov 15:S0302-2838(24)02687-3. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
98. KISHAN AU, Lamb JM, Wilhalme H, Casado M, et al
    Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.
    Eur Urol. 2024 Nov 12:S0302-2838(24)02688-5. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
99. GHADJAR P, Zips D
    Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial.
    Eur Urol. 2024 Nov 12:S0302-2838(24)02691-5. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
100. ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
     Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [
     Eur Urol. 2024 Nov 8:S0302-2838(24)02684-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
101. PARKER CC, Clarke NW, Cook AD, Petersen PM, et al
     Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047).
     Eur Urol. 2024;86:422-430.
     PubMed     Abstract available
     
     
     
102. LANE BR, Dess RT, Borza T
     More Than Words: Defining Adjuvant, Consolidative, and Salvage Treatment after Radical Prostatectomy.
     Eur Urol. 2024;86:385-387.
     PubMed     Abstract available
     
     
     October 2024
103. OH WK, Agarwal N, Bryce A, Barata P, et al
     What's in a Name? Why Words Matter in Advanced Prostate Cancer.
     Eur Urol. 2024 Oct 28:S0302-2838(24)02680-0. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
104. TOUIJER KA, Vertosick EA, Sjoberg DD, Liso N, et al
     Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.
     Eur Urol. 2024 Oct 28:S0302-2838(24)02647-2. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
105. TWILT JJ, Saha A, Bosma JS, van Ginneken B, et al
     Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study.
     Eur Urol. 2024 Oct 21:S0302-2838(24)02640-X. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
106. VANDERWEELE DJ, Hussain M
     Management Decisions for Metastatic Castration-resistant Prostate Cancer in 2024.
     Eur Urol. 2024 Oct 19:S0302-2838(24)02646-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
107. EVANGELISTA L, Cecchi L, Zucali PA
     Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen-based Radioligand Therapy at the Forefront.
     Eur Urol. 2024 Oct 19:S0302-2838(24)02645-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
108. FENDLER WP, Grunwald V, Herrmann K, Hadaschik BA, et al
     Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer.
     Eur Urol. 2024 Oct 19:S0302-2838(24)02648-4. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
109. GILLESSEN S, Turco F, Davis ID, Efstathiou JA, et al
     Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
     Eur Urol. 2024 Oct 10:S0302-2838(24)02610-1. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
110. BAKHT MK, Beltran H
     Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naive Prostate Cancer.
     Eur Urol. 2024 Oct 10:S0302-2838(24)02637-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
111. ONG WL, Loblaw A
     Radiotherapy for Unfavorable-risk Prostate Cancer: Biologic Dose Escalation, Fewer Fractions, or Both?
     Eur Urol. 2024 Oct 9:S0302-2838(24)02636-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
112. ROUVIERE O, van Leenders GJLH, Eberli D
     Systematic Prostate Biopsy Versus Perilesional Sampling: If It Isn't Broke, Why Fix It?
     Eur Urol. 2024;86:295-296.
     PubMed     Abstract available
     
     
     
113. BROWN JR, Sonpavde GP, Calaway A, Barata PC, et al
     Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
     Eur Urol. 2024;86:312-314.
     PubMed    
     
     
     
114. CIMADAMORE A, Giannarini G, Crestani A, Lopez-Beltran A, et al
     How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the "Tertiary" Terminology?
     Eur Urol. 2024;86:291-294.
     PubMed     Abstract available
     
     
     September 2024
115. GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
     Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer.
     Eur Urol. 2024 Sep 26:S0302-2838(24)02613-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
116. CARLSSON SV, Lilja H, Vickers AJ, Bjartell AS, et al
     Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk.
     Eur Urol. 2024 Sep 25:S0302-2838(24)02615-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
117. QI F
     Re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
     Eur Urol. 2024 Sep 25:S0302-2838(24)02612-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
118. VAN DEN BERGH RCN, Schoots IG, Cornford PA
     Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?
     Eur Urol. 2024 Sep 25:S0302-2838(24)02607-1. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
119. DAI YH, Chen PH, Lee DJ, Andrade G, et al
     A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer.
     Eur Urol. 2024 Sep 25:S0302-2838(24)02608-3. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
120. RATHKOPF DE, Roubaud G, Chi KN, Efstathiou E, et al
     Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
     Eur Urol. 2024 Sep 23:S0302-2838(24)02594-6. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
121. UNTERRAINER M, Unterrainer LM, Ilhan H
     Re: Robert Seifert, Louise Emmett, Steven P. Rowe, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023;83:405-12.
     Eur Urol. 2024 Sep 23:S0302-2838(24)02617-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
122. KLUMPER N, Eckstein M
     Reply to Feng Qi's Letter to the Editor re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy
     Eur Urol. 2024 Sep 23:S0302-2838(24)02616-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
123. CHEN DC, Thomson A, Mazzone E, Perera ML, et al
     Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
     Eur Urol. 2024 Sep 20:S0302-2838(24)02513-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
124. FRANCINI E, Agarwal N, Castro E, Cheng HH, et al
     Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review.
     Eur Urol. 2024 Sep 20:S0302-2838(24)02599-5. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
125. BOEVE LMS, Hulshof MCCM, Verhagen PCMS, Twisk JWR, et al
     Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.
     Eur Urol. 2024 Sep 19:S0302-2838(24)02593-4. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
126. AZIZ MK, Molony D, Monlezun D, Holder T, et al
     Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.
     Eur Urol. 2024 Sep 18:S0302-2838(24)02569-7. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
127. WEINER AB, Agrawal R, Wang NK, Sonni I, et al
     Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naive Prostate Cancer.
     Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
128. BJERNER J, Bratt O, Aas K, Albertsen PC, et al
     Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the No
     Eur Urol. 2024 Sep 17:S0302-2838(24)02575-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
129. BRATT O
     Prostate Cancer Screening: Setting the Controls on the Mixing Board.
     Eur Urol. 2024 Sep 17:S0302-2838(24)02598-3. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
130. NIAZI T, Nabid A, Malagon T, Tisseverasinghe S, et al
     Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Genito-urinaire du Quebec-led Phase 3 Trial.
     Eur Urol. 2024 Sep 12:S0302-2838(24)02574-0. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
131. VAN AS N, Yasar B, Griffin C, Patel J, et al
     Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.
     Eur Urol. 2024 Sep 11:S0302-2838(24)02568-5. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
132. LI R, Peng L, Zhang S, Wu S, et al
     Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20-6.
     Eur Urol. 2024 Sep 5:S0302-2838(24)02564-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
133. ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al
     Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.
     Eur Urol. 2024 Sep 5:S0302-2838(24)02560-0. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
134. NAIR SS, Muhammad H, Jain P, Xie C, et al
     A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.
     Eur Urol. 2024 Sep 3:S0302-2838(24)02496-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
135. KASIVISVANATHAN V, Wai-Shun Chan V, Clement KD, Levis B, et al
     VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.
     Eur Urol. 2024 Sep 3:S0302-2838(24)02559-4. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
136. VYNCKIER P, Annemans L, Roobol M
     Reply to Andres Gutierrez, Julio Cesar Boada, and Sebastian Pena's Letter to the Editor re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost-effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. ht
     Eur Urol. 2024 Sep 2:S0302-2838(24)02566-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
137. ACHARD V, Tombal B
     All Biochemical Recurrences Are Equal, but Some Are More Equal than Others.
     Eur Urol. 2024;86:211-212.
     PubMed    
     
     
     August 2024
138. GUTIERREZ A, Boada JC, Pena S
     Re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.04.036.
     Eur Urol. 2024 Aug 30:S0302-2838(24)02565-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
139. LEENEN RCA, Venderbos LDF, Helleman J, Gomez Rivas J, et al
     Prostate Cancer Early Detection in the European Union and UK.
     Eur Urol. 2024 Aug 24:S0302-2838(24)02502-8. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
140. QI F
     Re: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter R
     Eur Urol. 2024 Aug 21:S0302-2838(24)02557-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
141. MAY M, Albersen M, Brookman-May S
     Re: Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
     Eur Urol. 2024 Aug 19:S0302-2838(24)02552-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
142. BRATT O
     Re: Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
     Eur Urol. 2024 Aug 17:S0302-2838(24)02523-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
143. CHEN DC, Park H, McVey A, Lawrentschuk N, et al
     Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
     Eur Urol. 2024 Aug 17:S0302-2838(24)02520-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
144. GORADIA R, Abdollah F, Sood A
     Re: Integrative Multi-Region Molecular Profiling of Primary Prostate Cancer in Men with Synchronous Lymph Node Metastasis.
     Eur Urol. 2024 Aug 6:S0302-2838(24)02497-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
145. KAMRAN SC, Efstathiou JA
     Honing Stratification and Treatment for High-risk Prostate Cancer.
     Eur Urol. 2024 Aug 6:S0302-2838(24)02489-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
146. DI LORENZO G, Buonerba C
     Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
     Eur Urol. 2024 Aug 1:S0302-2838(24)02500-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
147. THOMPSON IM JR
     Prostate-specific Antigen Screening in Limbo: How Low Should We Go?
     Eur Urol. 2024;86:101-102.
     PubMed    
     
     
     
148. MARRA G, Oderda M, Gontero P
     Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
     Eur Urol. 2024;86:e36-e37.
     PubMed    
     
     
     July 2024
149. MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al
     Re: Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
     Eur Urol. 2024 Jul 31:S0302-2838(24)02492-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
150. PARK H, Chen DC, Mazzone E, Grummet J, et al
     Re: Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening. The STHLM3-MRI Randomized Clinical Trial.
     Eur Urol. 2024 Jul 19:S0302-2838(24)02452-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
151. MAZZONE E, Perera S, Neti AL, Chen DC, et al
     Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
     Eur Urol. 2024 Jul 19:S0302-2838(24)02450-3. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
152. SPRATT DE, Liu VYT, Jia AY, Royce TJ, et al
     Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials.
     Eur Urol. 2024 Jul 17:S0302-2838(24)02454-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
153. HU JC, Schaeffer EM, Vickers AJ
     Reply to Ilias Giannakodimos' Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREV
     Eur Urol. 2024;86:e13.
     PubMed    
     
     
     
154. ROSEN GH, Chakiryan NH, Murray KS
     Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
     Eur Urol. 2024;86:e14.
     PubMed    
     
     
     
155. GIANNAKODIMOS I
     Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
     Eur Urol. 2024;86:e12.
     PubMed    
     
     
     
156. CHIU PK, Wu X, Gandaglia G
     Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate Biopsies.
     Eur Urol. 2024;86:e16-e17.
     PubMed    
     
     
     
157. HU JC, Assel M, Allaf ME, Ehdaie B, et al
     Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.
     Eur Urol. 2024;86:61-68.
     PubMed     Abstract available
     
     
     June 2024
158. TANEJA SS
     Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic Resonance Imaging-targeted Biopsy on Prostate Cancer Mortality?
     Eur Urol. 2024 Jun 19:S0302-2838(24)02413-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
159. COOPERBERG MR
     PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
     Eur Urol. 2024 Jun 18:S0302-2838(24)02400-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
160. SRIVASTAVA A, Lewicki P, Morgan TM
     Biomarkers in Prostate Cancer Screening: Sometimes "More is More".
     Eur Urol. 2024 Jun 18:S0302-2838(24)02428-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
161. RAYCHAUDHURI R, DeJong M, Rettig M, Yu EY, et al
     Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial.
     Eur Urol. 2024 Jun 17:S0302-2838(24)02407-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
162. MACEK P, Rodriguez-Sanchez L, Cathelineau X
     Re: Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of
     Eur Urol. 2024 Jun 13:S0302-2838(24)02401-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
163. ADELEKE S
     High-performing, Accessible, and Affordable Imaging in Metastatic Prostate Cancer: Is Whole-body Magnetic Resonance Imaging the Answer?
     Eur Urol. 2024 Jun 12:S0302-2838(24)02410-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     May 2024
164. VICKERS AJ
     Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
     Eur Urol. 2024 May 25:S0302-2838(24)02385-6. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
165. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
     Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Roder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer L
     Eur Urol. 2024 May 24:S0302-2838(24)02387-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
166. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
     Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In
     Eur Urol. 2024 May 24:S0302-2838(24)02386-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
167. VYNCKIER P, Annemans L, Raes S, Amrouch C, et al
     Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
     Eur Urol. 2024 May 23:S0302-2838(24)02378-9. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
168. WEINER AB, Kakani P, Armstrong AJ, Bossi A, et al
     Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review.
     Eur Urol. 2024 May 22:S0302-2838(24)02375-3. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
169. RAVI P, Xie W, Buyse M, Halabi S, et al
     Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
     Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
170. DALLA VOLTA A, Valcamonico F, Zivi A, Procopio G, et al
     Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
     Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
171. JOSEFSSON A, Mansson M, Kohestani K, Spyratou V, et al
     Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial.
     Eur Urol. 2024 May 20:S0302-2838(24)02379-0. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
172. BROOKMAN-MAY SD, Buyse M, Freedland SJ, Miladinovic B, et al
     Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer.
     Eur Urol. 2024 May 17:S0302-2838(24)02348-0. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
173. PADHANI AR, Lecouvet F, Petralia G, Koh DM, et al
     Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. http
     Eur Urol. 2024 May 16:S0302-2838(24)02377-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
174. GARCIA-RUIZ A, Macarro C, Mateo J, Perez-Lopez R, et al
     Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castrati
     Eur Urol. 2024 May 16:S0302-2838(24)02376-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
175. FANKHAUSER CD, Wettstein MS, Wurnschimmel C, van Smeden M, et al
     Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
     Eur Urol. 2024 May 15:S0302-2838(24)02340-6. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
176. KRILAVICIUTE A, Kaaks R, Seibold P, de Vrieze M, et al
     Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
     Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
177. STROOMBERG HV, Brasso K, Roder A
     Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
     Eur Urol. 2024 May 14:S0302-2838(24)02365-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
178. MERSEBURGER AS, Chowdhury S, Bahl A
     Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study.
     Eur Urol. 2024 May 14:S0302-2838(24)02364-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
179. CHIN JL
     Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database.
     Eur Urol. 2024 May 13:S0302-2838(24)02344-3. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
180. KLUMPER N, Grunwald V, Hartmann A, Holzel M, et al
     The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
     Eur Urol. 2024 May 13:S0302-2838(24)02350-9. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
181. OKOLI S, Okoli O, Ding H, Adeleke S, et al
     Re: Actinium-225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer (WARMTH Act): A Multicentre, Retrospective Study.
     Eur Urol. 2024 May 11:S0302-2838(24)02352-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
182. LIGHT A, Mayor N, Cullen E, Kirkham A, et al
     The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
     Eur Urol. 2024;85:466-482.
     PubMed     Abstract available
     
     
     
183. ANAND M, Jain B, Aggarwal S
     Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
     Eur Urol. 2024;85:e145.
     PubMed    
     
     
     
184. HARTRAMPF PE, Rowe SP, Pomper MG, Higuchi T, et al
     Reply to Madhur Anand, Bela Jain, and Swati Aggarwal's Letter to the Editor re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-Specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
     Eur Urol. 2024;85:e146-e147.
     PubMed    
     
     
     April 2024
185. TILKI D, van den Bergh RCN, Briers E, Van den Broeck T, et al
     EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
     Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
186. OST P, Siva S, Zilli T
     OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
     Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
187. HU JC, Vickers AJ, Schaeffer EM
     Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate
     Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
188. CHAKRABARTI D, Parker CC
     Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.
     Eur Urol. 2024 Apr 26:S0302-2838(24)02308-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
189. SAAD F, Hussain MHA, Tombal B, Fizazi K, et al
     Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of
     Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
190. HINDIE E, Champion C, Morgat C
     Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. In press.
     Eur Urol. 2024 Apr 20:S0302-2838(24)02310-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
191. CARDONA ORTEGON JD, Campana Perilla LA, Olarte Bermudez LM
     Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105-11
     Eur Urol. 2024 Apr 20:S0302-2838(24)02315-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
192. CORNFORD P, van den Bergh RCN, Briers E, Van den Broeck T, et al
     EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
     Eur Urol. 2024 Apr 12:S0302-2838(24)02254-1. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
193. GRABBERT M, Liakos N, Gratzke C
     Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
     Eur Urol. 2024 Apr 11:S0302-2838(24)02258-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
194. RUSH HL, Gilbert DC, Langley RE
     Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
     Eur Urol. 2024 Apr 6:S0302-2838(24)02251-6. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
195. ROY S, Fervaha G, Spratt DE, Sun Y, et al
     Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
     Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
196. ROY S, Saad F, Malone S, Agarwal N, et al
     Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
     Eur Urol. 2024;85:398-400.
     PubMed    
     
     
     
197. O'CALLAGHAN M, Bulamu N, Gormly K, Jay A, et al
     Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.
     Eur Urol. 2024;85:395.
     PubMed    
     
     
     March 2024
198. ENGLMAN C, Maffei D, Allen C, Kirkham A, et al
     PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
     Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
199. LOGOTHETIS CJ, Hahn AW
     Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024
     Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
200. WASSERSUG RJ, Schellhammer PF, Wibowo E
     Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
     Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
201. WINDISCH O, Valerio M
     Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
     Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
202. DE MEERLEER G, Joniau S, Benijts J, Rans K, et al
     Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
     Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
203. BURGER M
     Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Pro
     Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
204. NIKITAS J, Rettig M, Shen J, Reiter R, et al
     Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
     Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
205. BABOUDJIAN M, Diamand R, Uleri A, Beauval JB, et al
     Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
     Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
206. CUSSENOT O, Chambaz A, Hamdy FC
     Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur
     Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
207. GARCIA-RUIZ A, Macarro C, Zacchi F, Morales-Barrera R, et al
     Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
     Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
208. MOLLER F, Mansson M, Wallstrom J, Hellstrom M, et al
     Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
     Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
209. WEBER M, Fendler WP, Ravi Kumar AS, Calais J, et al
     Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
     Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
210. VAUGIER L, Morvan C, Pasquier D, Buthaud X, et al
     Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
     Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
211. NICKOLS NG, Tsai S, Kane N, Tran S, et al
     Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
     Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
212. MONTIRONI R, Cimadamore A, Giannarini G, Crestani A, et al
     Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population.
     Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
213. FODOR A, Brombin C, Chiti A, Di Muzio N, et al
     Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press. https://doi.org/1
     Eur Urol. 2024 Mar 12:S0302-2838(24)02140-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
214. SARTOR O
     Prostate-specific Membrane Antigen-targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution.
     Eur Urol. 2024;85:205-206.
     PubMed    
     
     
     
215. PILATZ A, MacLennan S, van den Bergh RCN, Veeratterapillay R, et al
     Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99-100.
     Eur Urol. 2024;85:313-314.
     PubMed    
     
     
     February 2024
216. GOLIJANIN B, Mega A, Golijanin D
     Re: Ivo I. de Vos II, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Scr
     Eur Urol. 2024 Feb 29:S0302-2838(24)00081-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
217. POPE B, Park G, Lau E, Belic J, et al
     Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
     Eur Urol. 2024 Feb 19:S0302-2838(24)00003-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
218. FENG D, Wang J, Wu R, Li D, et al
     Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen Deprivation Therapy Against Prostate Cancer.
     Eur Urol. 2024 Feb 17:S0302-2838(24)00069-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
219. DE VOS II, Remmers S, Roobol MJ
     Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinui
     Eur Urol. 2024 Feb 17:S0302-2838(24)00057-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
220. DEIVASIGAMANI S, Kotamarti S, Gupta RT, Polascik TJ, et al
     Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization?
     Eur Urol. 2024;85:180-181.
     PubMed    
     
     
     
221. PREISSER F, Abrams-Pompe RS, Stelwagen PJ, Bohmer D, et al
     European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
     Eur Urol. 2024;85:164-170.
     PubMed     Abstract available
     
     
     
222. MIAN BM
     Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise.
     Eur Urol. 2024;85:99-100.
     PubMed     Abstract available
     
     
     January 2024
223. ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
     Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
     Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
224. VICKERS AJ, Assel M, Cooperberg MR, Fine SW, et al
     Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.
     Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
225. CHI KN, Armstrong AJ, Krause BJ, Herrmann K, et al
     Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
     Eur Urol. 2024 Jan 6:S0302-2838(23)03297-9. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     December 2023
226. LIU M, Chen P, Li T
     Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
     Eur Urol. 2023 Dec 21:S0302-2838(23)03293-1. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
227. HUANG TB, Ding XF
     Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial, Eur Urol. In press. htt
     Eur Urol. 2023 Dec 16:S0302-2838(23)03294-3. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
228. ALBERS P, van Poppel H
     Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program.
     Eur Urol. 2023 Dec 15:S0302-2838(23)03290-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
229. CORPETTI M, Muller C, Beltran H, de Bono J, et al
     Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes.
     Eur Urol. 2023 Dec 15:S0302-2838(23)03278-5. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
230. FERNANDEZ-ZAPATA WF, Gandur Quiroga MN, Cardona Maya WD
     Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
     Eur Urol. 2023 Dec 11:S0302-2838(23)03283-9. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
231. RAGGI D, Cigliola A, Mercinelli C, Patane D, et al
     Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials.
     Eur Urol. 2023 Dec 11:S0302-2838(23)03260-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
232. KAPLAN-MARANS E, Zhang TR, Hu JC
     Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budaus's Letter to the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European A
     Eur Urol. 2023;84:e151.
     PubMed    
     
     
     
233. CAPOGROSSO P, Deho F, Salonia A, Briganti A, et al
     Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534-47.
     Eur Urol. 2023;84:e146.
     PubMed    
     
     
     
234. DJAILEB L, Armstrong WR, Thompson D, Gafita A, et al
     Presurgical (68)Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
     Eur Urol. 2023;84:588-596.
     PubMed     Abstract available
     
     
     
235. SAAD F, Del Rosario P, Clarke NW
     Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespe
     Eur Urol. 2023 Dec 1:S0302-2838(23)03274-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
236. BRATT O, Godtman RA, Jiborn T, Wallstrom J, et al
     Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men.
     Eur Urol. 2023 Dec 1:S0302-2838(23)03272-4. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
237. FALKENBACH F, Sanguedolce F, Budaus L
     Re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:44
     Eur Urol. 2023;84:e149-e150.
     PubMed    
     
     
     November 2023
238. GIESEN A, Devlies W, Claessens F, Joniau S, et al
     Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.
     Eur Urol. 2023 Nov 27:S0302-2838(23)03273-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
239. DING L, Yang B, Yao X
     Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
     Eur Urol. 2023 Nov 23:S0302-2838(23)03226-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
240. MUN CHOW K, Zheng So W, Jie Lee H, Lee A, et al
     Corrigendum to "Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic R
     Eur Urol. 2023 Nov 14:S0302-2838(23)03213-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
241. MOORE CM, Albertsen P
     When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen.
     Eur Urol. 2023 Nov 13:S0302-2838(23)03212-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
242. HAMDY FC, Donovan JL
     Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:
     Eur Urol. 2023 Nov 8:S0302-2838(23)03218-9. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
243. MISZCZYK M, Rajwa P, Yanagisawa T, Nowicka Z, et al
     The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
     Eur Urol. 2023 Nov 7:S0302-2838(23)03209-8. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
244. TRUJILLO CG, Pena Rodriguez S, Diaz Ritter C
     Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol. 2023;83:534-47.
     Eur Urol. 2023;84:e116.
     PubMed    
     
     
     
245. FENG T, Ren M, Zhou Z
     Re: Peter Fletcher, Marta De Santis, Simona Ippoliti, et al. Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia. Eur Urol 2023
     Eur Urol. 2023;84:e114.
     PubMed    
     
     
     
246. LINDER S, Severson TM, van der Mijn KJC, Nevedomskaya E, et al
     Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
     Eur Urol. 2023;84:455-460.
     PubMed     Abstract available
     
     
     
247. WERNER RA, Hartrampf PE, Fendler WP, Serfling SE, et al
     Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
     Eur Urol. 2023;84:491-502.
     PubMed     Abstract available
     
     
     October 2023
248. DE VOS II, Remmers S, Hogenhout R, Roobol MJ, et al
     Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
     Eur Urol. 2023 Oct 31:S0302-2838(23)03207-4. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
249. SHAW G, Kelly JD, Roobol MJ
     Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
     Eur Urol. 2023 Oct 26:S0302-2838(23)03170-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
250. EAPEN RS, Buteau JP, Jackson P, Mitchell C, et al
     Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
     Eur Urol. 2023 Oct 25:S0302-2838(23)03087-7. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
251. SHARMA AD, Good DW, Alan McNeill S
     Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
     Eur Urol. 2023 Oct 19:S0302-2838(23)03157-3. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
252. BOSCHHEIDGEN M, Albers P, Schlemmer HP, Hellms S, et al
     Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
     Eur Urol. 2023 Oct 18:S0302-2838(23)03158-5. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
253. HERLEMANN A, Cowan JE, Washington SL 3rd, Wong AC, et al
     Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
     Eur Urol. 2023 Oct 17:S0302-2838(23)03155-X. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
254. SORCE G, Mottrie A
     Re: Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study that Challenges the Dogma.
     Eur Urol. 2023 Oct 14:S0302-2838(23)03159-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
255. GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
     Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2
     Eur Urol. 2023 Oct 11:S0302-2838(23)03140-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
256. KRAFFT U, Hadaschik BA, Luckerath K, Herrmann K, et al
     A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
     Eur Urol. 2023 Oct 11:S0302-2838(23)03149-4. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
257. TOMBAL B, Collins S, Morgans AK, Hunsche E, et al
     Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
     Eur Urol. 2023 Oct 11:S0302-2838(23)03099-3. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
258. JUNG J, Kim JH
     Re: Casey Crump, Par Stattin, James D. Brooks, et al. Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study. Eur Urol 2023;84:263-72.
     Eur Urol. 2023 Oct 11:S0302-2838(23)03154-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
259. HICKS RJ
     The Pythia Speaks on Prostate Cancer Diagnosis and Treatment.
     Eur Urol. 2023 Oct 11:S0302-2838(23)03148-2. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
260. KISHAN AU, Valle LF, Marks LS
     Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in Radiorecurrent Prostate Cancer.
     Eur Urol. 2023 Oct 5:S0302-2838(23)03145-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
261. COLE AP, Gupta N, Loeb S
     The Plant-based Prescription: How Dietary Change Can Improve Both Urological and Planetary Health.
     Eur Urol. 2023;84:357-358.
     PubMed     Abstract available
     
     
     
262. HEIJNSDIJK EAM, de Koning HJ
     Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach.
     Eur Urol. 2023;84:359-360.
     PubMed    
     
     
     September 2023
263. LIGHT A, Kanthabalan A, Otieno M, Pavlou M, et al
     The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
     Eur Urol. 2023 Sep 29:S0302-2838(23)03089-0. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
264. LAMBERT E, Roupret M
     Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
     Eur Urol. 2023 Sep 27:S0302-2838(23)03137-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
265. BEATRICI E, Labban M, Stone BV, Filipas DK, et al
     Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base.
     Eur Urol. 2023 Sep 25:S0302-2838(23)03088-9. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
266. PONTES-SILVA A
     Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
     Eur Urol. 2023 Sep 25:S0302-2838(23)03094-4. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
267. ILIE G, Rutledge RDH
     Reply to Andre Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Tr
     Eur Urol. 2023 Sep 22:S0302-2838(23)03091-9. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
268. MAY M, Wolff I, Brookman-May SD
     Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
     Eur Urol. 2023 Sep 22:S0302-2838(23)03095-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
269. KLOTZ L
     Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.
     Eur Urol. 2023 Sep 22:S0302-2838(23)03080-4. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
270. OPREA-LAGER DE, MacLennan S, Bjartell A, Briganti A, et al
     European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
     Eur Urol. 2023 Sep 22:S0302-2838(23)03092-0. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
271. ILIE G, Rutledge RDH
     Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Un
     Eur Urol. 2023 Sep 22:S0302-2838(23)03093-2. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
272. VAN POPPEL H, Roobol MJ, Chandran A
     Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.
     Eur Urol. 2023 Sep 11:S0302-2838(23)03023-3. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
273. MICHEL MC
     Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening.
     Eur Urol. 2023 Sep 9:S0302-2838(23)03081-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
274. ROCCO B, Sighinolfi MC
     Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-58.
     Eur Urol. 2023 Sep 6:S0302-2838(23)03069-5. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     August 2023
275. PAPACHRISTODOULOU A, Heidegger I, Virk RK, Di Bernardo M, et al
     Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.
     Eur Urol. 2023 Aug 31:S0302-2838(23)03016-6. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
276. HAMDY FC, Donovan JL
     Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-
     Eur Urol. 2023 Aug 31:S0302-2838(23)03070-1. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.